Celator granted U.S. Patent covering CombiPlex technology platform

Dec 17 2010

Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator's innovative technology platforms and products.

“We're pleased to receive this patent which broadly protects Celator's CombiPlex technology, the foundation of our current product pipeline”

U.S. Patent No. 7,850,990 covers the CombiPlex^® technology platform, the basis for Celator's two clinical-stage products. CombiPlex is a unique approach using drug carriers (nano-scale liposomes) to deliver synergistic ratios of drug combinations for the treatment of cancer. Celator's research identified that different ratios of the same drugs can be synergistic, additive, or antagonistic. In contrast to conventional combination drug regimens, which do not take this potential into account, CombiPlex identifies a synergistic ratio of the drugs and locks that combination in nano-scale (about 100 times smaller than a red blood cell) carriers that are able to deliver and maintain the synergistic drug ratio after injection into patients. This extended delivery of a synergistic ratio of drugs is intended to increase the effectiveness of the combination and improve clinical outcomes.

"We're pleased to receive this patent which broadly protects Celator's CombiPlex technology, the foundation of our current product pipeline," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "Our lead investigational product, CPX-351, recently reported positive Phase 2 data and planning is underway for Phase 3. With the Patent Term Adjustment, this patent provides protection until January 2027, which significantly extends market exclusivity for CPX-351."